BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...trial of FX-322 in 2H20. The small molecule combination therapy pairs the approved HDAC inhibitor sodium valproate...
BioCentury | Feb 4, 2013
Company News

SciClone, Sanofi sales and marketing update

...SciClone exclusive commercialization rights to four of its products in China. The products are Depakine sodium valproate...
BioCentury | Aug 1, 2011
Clinical News

Trobalt retigabine regulatory update

...not responded well to the following drugs: carbamazepine, clobazam, gabapentin, lamotrigine , levetiracetam , oxcarbazepine, sodium valproate...
BioCentury | Jun 27, 2011
Clinical News

Depakene sodium valproate regulatory update

...label for Depakene sodium valproate from Kyowa Hakko Kirin to suppress the onset of migraine attacks. Depakene...
...manic disorder and bipolar disorder. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Depakene sodium valproate...
BioCentury | Jun 20, 2011
Clinical News

Potiga ezogabine regulatory update

...have not responded well to the following drugs: carbamazepine, clobazam, gabapentin, lamotrigine , levetiracetam, oxcarbazepine, sodium valproate...
BioCentury | Jun 17, 2011
Company News

NICE recommends Trobalt for seizures

...have not responded well to the following drugs: carbamazepine, clobazam, gabapentin, lamotrigine , levetiracetam, oxcarbazepine, sodium valproate...
BioCentury | Jan 19, 2004
Clinical News

Lamictal lamotrigine regulatory update

...treat partial seizures in patients ages 16 and older when converting from valproate, which includes Depakene...
Items per page:
1 - 7 of 7